Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE N/A. (2011–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $40M | $80M | $82M | $99M | $278M | $483M | $1.1B | $1.2B | $532M | $440M | $352M |
| Enterprise Value | $213M | $254M | $214M | $224M | $322M | $473M | $1.2B | $1.2B | $516M | $371M | $303M |
| P/E Ratio → | -0.10 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.27 | 0.55 | 0.57 | 0.68 | 1.77 | 2.30 | 10.30 | 29.01 | 17.53 | 274.25 | 2287.93 |
| P/B Ratio | — | — | — | — | — | — | 22.04 | 23.84 | 2.90 | 3.40 | 2.17 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.74 | 1.48 | 1.53 | 2.05 | 2.25 | 10.72 | 28.91 | 17.02 | 231.27 | 1965.44 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 95.9% | 95.9% | 95.9% | 96.6% | 96.7% | 98.4% | 97.5% | 94.1% | -431.9% | -6583.7% | -56353.2% |
| Operating Margin | -62.1% | -62.1% | -82.2% | -88.7% | -90.5% | -46.8% | -159.0% | -462.9% | -593.0% | -8133.2% | -71903.9% |
| Net Profit Margin | -134.2% | -134.2% | -52.6% | -98.0% | -105.2% | -59.1% | -181.6% | -488.1% | -588.1% | -8036.4% | -71153.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | -391.3% | -171.4% | -114.1% | -88.4% | -60.8% |
| ROA | -143.7% | -143.7% | -37.8% | -47.8% | -49.8% | -40.1% | -64.6% | -62.7% | -68.4% | -71.5% | -55.4% |
| ROIC | — | — | — | -1229.1% | -391.7% | -2376.0% | -182.3% | -133.0% | -118.2% | -113.2% | -65.8% |
| ROCE | -205.0% | -205.0% | -98.3% | -55.9% | -54.3% | -40.6% | -68.5% | -69.7% | -84.6% | -88.6% | -60.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | 2.59 | 2.51 | 0.56 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | — | — | 0.89 | -0.08 | -0.08 | -0.53 | -0.31 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -3.27 | -3.27 | -1.04 | -4.99 | -5.60 | -3.75 | -6.22 | -11.75 | -70.55 | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.12 | 1.12 | 1.70 | 3.37 | 5.31 | 3.74 | 4.59 | 6.01 | 7.13 | 3.00 | 7.99 |
| Quick Ratio | 1.08 | 1.08 | 1.64 | 3.32 | 5.25 | 3.68 | 4.55 | 6.00 | 7.13 | 3.00 | 7.99 |
| Cash Ratio | 0.69 | 0.69 | 1.18 | 2.76 | 4.22 | 3.10 | 4.14 | 5.65 | 7.00 | 2.96 | 7.86 |
| Asset Turnover | — | 1.35 | 0.88 | 0.61 | 0.44 | 0.69 | 0.35 | 0.14 | 0.09 | 0.01 | 0.00 |
| Inventory Turnover | 1.47 | 1.47 | 1.27 | 1.62 | 1.23 | 0.83 | 1.02 | 6.96 | — | — | — |
| Days Sales Outstanding | — | 65.42 | 77.32 | 67.39 | 109.42 | 39.14 | 43.50 | 70.17 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $11M | $8M | $8M | $5M | $5M | $5M | $4M | $4M | $3M | $3M |
Includes 30+ ratios · 15 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying KPTI stock.
Karyopharm Therapeutics Inc.'s current P/E ratio is -0.1x. This places it at the 50th percentile of its historical range.
Based on historical data, Karyopharm Therapeutics Inc. is trading at a P/E of -0.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Karyopharm Therapeutics Inc. has 95.9% gross margin and -62.1% operating margin.
Key Metrics
Top Statement Risk
Liquidity and dilution risk
Metrics are mathematically derived from official filings.
Market Pricing Reflects Distressed Outlook
According to current market data, KPTI trades at a price-to-sales ratio of 0.60, which appears to reflect significant investor skepticism regarding the company's ability to achieve sustainable commercial scale or profitability in the near term compared to its oncology-focused peers.
The low P/S multiple suggests that the market is heavily discounting the company's future revenue streams, likely due to the persistent operating losses and the high risk of further equity dilution. Investors should monitor whether this valuation floor holds as the company attempts to pivot its pipeline toward higher-potential indications like myelofibrosis.
Gross Efficiency Overshadowed by Deficits
As reported in financial statements, Karyopharm maintains a gross margin consistently exceeding 95%, yet this high-level efficiency is fundamentally undermined by a deeply negative operating margin of -76.3% in the most recent quarter, indicating that commercialization costs remain disproportionate to current revenue levels.
The disconnect between high gross margins and negative operating margins suggests that the company is struggling to achieve the necessary operating leverage to cover its substantial R&D and SG&A expenditures. This structural imbalance warrants further investigation into whether the current commercial model can ever reach a break-even point without significant cost rationalization.
Working Capital Volatility Hinders Liquidity
Based on the company's reported figures, the cash conversion cycle has fluctuated significantly, reaching 138 days in 2025Q2, which highlights the operational challenges in managing receivables and inventory turnover within the highly competitive and complex oncology distribution landscape.
The erratic nature of the cash conversion cycle suggests that Karyopharm lacks consistent control over its working capital, which exacerbates the pressure on its already limited cash reserves. Investors should monitor whether management can stabilize these metrics to improve the predictability of their cash flow profile.
Narrowing Safety Margin for Operations
According to recent SEC filings, the company's current ratio has tightened to 1.08, leaving a minimal buffer to meet short-term obligations while the business continues to burn cash at a rate that threatens its long-term financial viability without external capital injections.
The proximity of the current ratio to unity indicates that the company's liquidity position is increasingly vulnerable to any unexpected delays in revenue recognition or milestone payments. This precarious state suggests that the firm may face significant refinancing risks if it cannot demonstrate a clear path to self-sustaining cash flow.
Misapplication of Gross Margin Metrics
The most commonly misapplied metric for Karyopharm is the gross margin, which, at over 95%, often leads investors to incorrectly assume that the company is nearing profitability, while it actually obscures the massive, unavoidable SG&A and R&D costs required to compete in the oncology market.
Relying on gross margin as a proxy for future earnings power is misleading in this business model, as it ignores the high fixed-cost nature of commercial-stage biotech. A more appropriate focus would be the operating cash burn rate relative to the remaining cash runway, which provides a more accurate assessment of the company's survival risk.